Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 7 studies | 26% ± 8% | |
endothelial cell | 4 studies | 22% ± 6% | |
astrocyte | 4 studies | 26% ± 8% | |
squamous epithelial cell | 3 studies | 31% ± 18% | |
goblet cell | 3 studies | 25% ± 3% | |
basal cell | 3 studies | 26% ± 8% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
intestine | 3 studies | 19% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 1354.60 | 1445 / 1445 | 100% | 39.03 | 183 / 183 |
intestine | 100% | 3287.00 | 966 / 966 | 100% | 55.50 | 527 / 527 |
lung | 100% | 2569.03 | 578 / 578 | 100% | 39.67 | 1155 / 1155 |
stomach | 100% | 1898.42 | 359 / 359 | 100% | 47.50 | 286 / 286 |
breast | 100% | 2217.27 | 459 / 459 | 100% | 42.42 | 1114 / 1118 |
pancreas | 100% | 1445.33 | 328 / 328 | 99% | 38.41 | 177 / 178 |
prostate | 100% | 1900.96 | 245 / 245 | 99% | 45.95 | 499 / 502 |
bladder | 100% | 1625.86 | 21 / 21 | 99% | 39.12 | 498 / 504 |
uterus | 100% | 1662.49 | 170 / 170 | 98% | 45.63 | 451 / 459 |
ovary | 100% | 1199.17 | 180 / 180 | 96% | 20.03 | 414 / 430 |
thymus | 100% | 1277.36 | 652 / 653 | 96% | 19.14 | 582 / 605 |
kidney | 100% | 1519.53 | 89 / 89 | 94% | 24.52 | 848 / 901 |
skin | 100% | 1619.70 | 1808 / 1809 | 87% | 18.87 | 411 / 472 |
liver | 100% | 1288.38 | 226 / 226 | 85% | 15.32 | 347 / 406 |
adrenal gland | 100% | 1054.77 | 257 / 258 | 76% | 11.85 | 174 / 230 |
brain | 76% | 490.08 | 2017 / 2642 | 63% | 9.07 | 441 / 705 |
adipose | 100% | 2394.77 | 1204 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 1685.54 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 45.63 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 8.24 | 1 / 1 |
blood vessel | 100% | 1252.38 | 1332 / 1335 | 0% | 0 | 0 / 0 |
muscle | 99% | 875.47 | 792 / 803 | 0% | 0 | 0 / 0 |
heart | 98% | 773.17 | 846 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 90% | 23.82 | 26 / 29 |
peripheral blood | 63% | 767.98 | 583 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 45% | 5.69 | 36 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0007507 | Biological process | heart development |
GO_0016485 | Biological process | protein processing |
GO_0009411 | Biological process | response to UV |
GO_0051146 | Biological process | striated muscle cell differentiation |
GO_0043525 | Biological process | positive regulation of neuron apoptotic process |
GO_0051402 | Biological process | neuron apoptotic process |
GO_0072734 | Biological process | cellular response to staurosporine |
GO_0006508 | Biological process | proteolysis |
GO_1905686 | Biological process | positive regulation of plasma membrane repair |
GO_0030163 | Biological process | protein catabolic process |
GO_0042742 | Biological process | defense response to bacterium |
GO_0071222 | Biological process | cellular response to lipopolysaccharide |
GO_0097194 | Biological process | execution phase of apoptosis |
GO_0006915 | Biological process | apoptotic process |
GO_0044346 | Biological process | fibroblast apoptotic process |
GO_0051604 | Biological process | protein maturation |
GO_0070227 | Biological process | lymphocyte apoptotic process |
GO_0005615 | Cellular component | extracellular space |
GO_0005634 | Cellular component | nucleus |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0008233 | Molecular function | peptidase activity |
GO_0097153 | Molecular function | cysteine-type endopeptidase activity involved in apoptotic process |
GO_0097200 | Molecular function | cysteine-type endopeptidase activity involved in execution phase of apoptosis |
GO_0003723 | Molecular function | RNA binding |
GO_0004190 | Molecular function | aspartic-type endopeptidase activity |
GO_0008234 | Molecular function | cysteine-type peptidase activity |
GO_0004197 | Molecular function | cysteine-type endopeptidase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | CASP7 |
Protein name | Caspase-7 (CASP-7) (EC 3.4.22.60) (Apoptotic protease Mch-3) (CMH-1) (ICE-like apoptotic protease 3) (ICE-LAP3) [Cleaved into: Caspase-7 subunit p20; Caspase-7 subunit p11] Caspase 7 |
Synonyms | MCH3 |
Description | FUNCTION: Thiol protease involved in different programmed cell death processes, such as apoptosis, pyroptosis or granzyme-mediated programmed cell death, by proteolytically cleaving target proteins . Has a marked preference for Asp-Glu-Val-Asp (DEVD) consensus sequences, with some plasticity for alternate non-canonical sequences . Its involvement in the different programmed cell death processes is probably determined by upstream proteases that activate CASP7 (By similarity). Acts as an effector caspase involved in the execution phase of apoptosis: following cleavage and activation by initiator caspases (CASP8, CASP9 and/or CASP10), mediates execution of apoptosis by catalyzing cleavage of proteins, such as CLSPN, PARP1, PTGES3 and YY1 . Compared to CASP3, acts as a minor executioner caspase and cleaves a limited set of target proteins . Acts as a key regulator of the inflammatory response in response to bacterial infection by catalyzing cleavage and activation of the sphingomyelin phosphodiesterase SMPD1 in the extracellular milieu, thereby promoting membrane repair . Regulates pyroptosis in intestinal epithelial cells: cleaved and activated by CASP1 in response to S.typhimurium infection, promoting its secretion to the extracellular milieu, where it catalyzes activation of SMPD1, generating ceramides that repair membranes and counteract the action of gasdermin-D (GSDMD) pores (By similarity). Regulates granzyme-mediated programmed cell death in hepatocytes: cleaved and activated by granzyme B (GZMB) in response to bacterial infection, promoting its secretion to the extracellular milieu, where it catalyzes activation of SMPD1, generating ceramides that repair membranes and counteract the action of perforin (PRF1) pores (By similarity). Following cleavage by CASP1 in response to inflammasome activation, catalyzes processing and inactivation of PARP1, alleviating the transcription repressor activity of PARP1 . Acts as an inhibitor of type I interferon production during virus-induced apoptosis by mediating cleavage of antiviral proteins CGAS, IRF3 and MAVS, thereby preventing cytokine overproduction (By similarity). Cleaves and activates sterol regulatory element binding proteins (SREBPs) . Cleaves phospholipid scramblase proteins XKR4, XKR8 and XKR9 (By similarity). In case of infection, catalyzes cleavage of Kaposi sarcoma-associated herpesvirus protein ORF57, thereby preventing expression of viral lytic genes . .; FUNCTION: [Isoform Beta]: Lacks enzymatic activity. . |
Accessions | ENST00000621345.4 [P55210-1] ENST00000672138.1 A0A0A0MRL7 ENST00000429617.5 ENST00000369331.8 [P55210-2] A0A5F9ZHZ6 ENST00000369321.6 ENST00000345633.8 [P55210-1] Q5SVL2 ENST00000614447.4 [P55210-2] ENST00000369315.5 [P55210-1] ENST00000369318.8 [P55210-1] P55210 ENST00000621607.4 [P55210-3] ENST00000452490.3 [P55210-4] |